AffaMed Therapeutics

Focus: AffaMed Therapeutics is an early-stage Chinese biotechnology company focused on small molecules and monoclonal antibodies for ophthalmology, currently in Series B with a single Phase 1 program.

Ophthalmology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

SERIES B

Open Jobs

About AffaMed Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow AffaMed Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

AM712

Neovascular Age-related Macular Degeneration

Phase 1

Clinical Trials (1)

NCT05345769Safety and Efficacy of AM712 in Patients with NAMD

Phase 1

Help build intelligence for AffaMed Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a Series B biotech with defined focus in high-unmet-need ophthalmology market
Exposure to dual modality platform (small molecules + mAbs) enables broad technical skill development
Early-stage company structure typically offers accelerated responsibility and direct impact on drug development decisions

Watch Out For

Single Phase 1 program (AM712) represents extremely early-stage pipeline with high clinical and commercial risk—no near-term value inflection points
No active hiring (0 open roles) and minimal public visibility suggest limited growth trajectory or capital constraints
China headquarters may present visa/relocation barriers for international talent and limited exit liquidity visibility (private, no ticker)

Generated by Claude from AffaMed Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2021

Portfolio: 1 clinical trial

Top TAs: Ophthalmology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Ophthalmology

1 pipeline

Marketed

Pipeline